Andre Goy | mantle cell lymphoma | Best Researcher Award

Dr. Andre Goy | mantle cell lymphoma | Best Researcher Award

John Theurer Cancer Center, United States

Author Profile

Early Academic Pursuits

Dr. Andre Goy's academic journey began with undergraduate studies at the University Joseph Fourier in Grenoble, France, where he laid the foundation for his medical career. He continued his education at Grenoble Medical School, obtaining his MD degree and subsequently pursued further studies in immunology and experimental oncology in France, including a certificate in immunology from the University Alexis Carrel and a master's degree from Paris X University and the Pasteur Institute.

Professional Endeavors

Dr. Goy's professional career is marked by a dedication to oncology and hematology. He completed internships and residencies at prestigious institutions in France, including Grenoble University Medical Center and Paris Hospital Cochin – Port Royal. He furthered his training through fellowships in both France and the United States, including positions at Memorial Sloan-Kettering Cancer Center in New York.

Contributions and Research Focus

Throughout his career, Dr. Goy has focused on advancing the understanding and treatment of lymphomas and other cancers. His research spans molecular hematology-oncology, tumor immunology, and translational cancer research. He has contributed significantly to the development of innovative therapies and biomarkers, particularly in the field of lymphoma.

Accolades and Recognition

Dr. Goy's contributions to oncology have been widely recognized, earning him numerous awards and honors. He has received board certifications in internal medicine, oncology, and hematology, both in the United States and France. He has been awarded prestigious positions, including the Lydia Pfund Chair for Lymphoma and appointments at esteemed institutions such as Georgetown University Medical Center.

Impact and Influence

Dr. Goy's impact extends beyond clinical practice and research. He has played key leadership roles in academic institutions and healthcare organizations, serving as Chairman and Chief Physician Officer of the John Theurer Cancer Center and Physician in Chief of the Hackensack Meridian Health Oncology Care Transformation Service. His leadership has shaped the direction of cancer care and research, impacting patient outcomes on a broad scale.

Legacy and Future Contributions

Dr. Goy's legacy is one of innovation, leadership, and dedication to improving cancer care. His contributions to research, education, and clinical practice have positioned him as a leading figure in the field of oncology. As he continues to lead and inspire others, his focus remains on advancing the understanding and treatment of cancer, ultimately improving the lives of patients worldwide.

Citations

A total of 29253 citations for his publications, demonstrating the impact and recognition of his research within the academic community.

  • Citations        29253
  • h-index          59
  • i10-index       60

Notable Publications 

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

A Ip, J Ahn, Y Zhou, AH Goy, E Hansen, AL Pecora, BA Sinclaire, ...
BMC infectious diseases

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

JY Spiegel, S Dahiya, MD Jain, J Tamaresis, LJ Nastoupil, MT Jacobs, ...
Blood, The Journal of the American Society of Hematology

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

OO Oluwole, K Bouabdallah, J Muñoz, S De Guibert, JM Vose, NL Bartlett, ...
British journal of haematology

Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma

ML Wang, W Jurczak, M Jerkeman, J Trotman, PL Zinzani, D Belada, ...
New England Journal of Medicine

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

N Biran, A Ip, J Ahn, RC Go, S Wang, S Mathura, BA Sinclaire, U Bednarz, ...
The Lancet Rheumatology

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

M Roschewski, MS Lionakis, JP Sharman, J Roswarski, A Goy, ...
Science immunology